Condition-Specific Health
Context Therapeutics Reports 29% Response Rate in PROC Phase 1 Trial
Interim RECIST v1.1 data from Context Therapeutics positions CTIM-76 as a clinical-stage candidate in a heavily pre-tre…
All 513 stories
Condition-Specific Health
ENA Respiratory Wins USPTO Patents for TLR2 Innate Immune Modulators
The allowances cover both composition-of-matter and method-of-use claims, strengthening IP position in the emerging inn…
Regulatory & Policy
Editor's Note: This Release Falls Outside Functional News Coverage
Functional News covers ingredients, finished formulations, clinical nutrition, and supplement regulation — not hospital…
Health & Wellness
AI in Radiology Gains Clinical Traction at HLTH Europe 2026
The Amsterdam showcase signals growing operator appetite for workflow-integrated AI diagnostics — a trend with downstre…
Condition-Specific Health
AI Radiology Model Debuts at HLTH Europe 2026
The Saudi hospital's presentation signals growing crossover between precision diagnostics and functional health monitor…
Condition-Specific Health
MHRA Clears Needle-Free Epinephrine Device for Pediatric Anaphylaxis
The MHRA approval expands emergency allergy management options for a pediatric population where needle-based delivery h…
Condition-Specific Health
Enterome's OncoMimics™ EO2463 Drives CD8 T Cell Response in Phase 1/2 Lymphoma Study
Microbiome-mimicry immunotherapy edges toward clinical validation — with implications for how gut-derived peptides may …
Science & Research
Orelabrutinib Data at EHA 2026: What Nutraceutical Formulators Should Know
As precision oncology expands BTK-inhibitor research, ingredient developers tracking immune-pathway mechanisms are watc…
Science & Research
Ascentage Pharma Posts 17 Clinical Updates at EHA2026
Data from Stockholm congress covers two China-approved oncology assets with implications for global development pipelin…
Condition-Specific Health
Barzolvolimab Phase 2 Data Show Durable CSU Remission Off-Treatment
Celldex's anti-KIT monoclonal antibody moves the goalposts from symptom control to potential disease modification — a s…
Condition-Specific Health
Lorundrostat Linked to Heart Failure Biomarker Reductions in Proteomic Analysis
Late-breaking findings presented at the Endocrine Society Annual Meeting add cardiovascular biomarker evidence to the a…
Condition-Specific Health
Verekitug Phase 2 Data Show 80% Responder Rate in Nasal Polyp Trial
The EAACI 2026 responder analysis adds to mounting evidence for targeted biologics in upper-airway inflammatory conditi…